Skip to main content
. 2022 Jul 22;10:947375. doi: 10.3389/fpubh.2022.947375

Table 2.

Base-case analysis results.

Strategies Cost Incr cost LYs Incr LYs ICER/LYs QALYs Incr QALYs ICER/QALYs
All patients group
Chemotherapy 95,715.26 0.65 0.58
Nivolumab plus ipilimumab 292,319.48 196,604.22 1.58 0.92 213,082.80 1.11 0.53 371,861.36

Incr cost, incremental cost; Lys, life-years; Incr Lys, incremental life-years; QALYs, quality-adjusted life-years; Incr QALYs, incremental quality-adjusted life-years; ICER, incremental cost-effectiveness ratio.